Navigation Links
A new treatment for kidney disease-associated heart failure?
Date:1/9/2013

Chronic kidney disease (CKD) patients frequently suffer from mineral bone disorder, which causes vascular calcification and, eventually, chronic heart failure. Similar to patients with CKD, mice with low levels of the protein klotho (klotho hypomorphic mice) also develop vascular calcification and have shorter life spans compared to normal mice. In this issue of the Journal of Clinical Investigation, Florian Lang and colleagues at the University of Tbingen in Germany, found that treatment with the mineralocorticoid receptor antagonist spironolactone reduced vascular calcification in klotho hypomorphic mice and increased their life span. In a companion Attending Physician article, Darryl Quarles of the University of Tennessee discusses the implications of these findings for the treatment of CKD patients.

TITLE:
Spironolactone-sensitive vascular calcification and Pit-1-dependent osteoblastic differentiation in klotho-hypomorphic mice

AUTHOR CONTACT:
Florian Lang
Dept. of Physiology, Tuebingen, NULL, DEU
Phone: +4970712972194; Fax: +497071295618; E-mail: florian.lang@uni-tuebingen.de

View this article at: http://www.jci.org/articles/view/64093?key=3010c850d2f970ad6617

ACCOMPANYING THE ATTENDING PHYSICIAN

TITLE:
Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new

AUTHOR CONTACT:
Darryl Quarles
University of Tennessee Health Science Center, memphis, TN, USA
Phone: 901-448-1459; Fax: 901-448-1188; E-mail: dquarles@uthsc.edu

View this article at: http://www.jci.org/articles/view/67203?key=054ae63743c930253936


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
2. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
3. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
4. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
5. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
8. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
9. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
10. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
11. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Francisco, CA (PRWEB) , ... December 03, 2016 ... ... grants to ground-breaking microbiome studies. A microbiome impact grant award has been made ... the effect of heavy smoking and drinking on the oral microbiome. Grant proposals ...
(Date:12/2/2016)... NORWALK, Conn. , Dec. 2, 2016  The ... research presentations from the MMRF CoMMpass Study SM —the ... and accelerating precision medicine in multiple myeloma—will be presented ... (ASH) Annual Meeting & Exposition in San ... are helping to optimize treatment strategies, as well as ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based medical device ... Class II 510(k) clearance for their flagship medical device, SimplECG. , With this ... devices that rely on cloth-based nanosensors. While other companies have attempted to focus ...
Breaking Biology Technology:
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
Breaking Biology News(10 mins):